Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: A randomized controlled trial
Articolo
Data di Pubblicazione:
2002
Citazione:
Clarithromycin versus azithromycin in the treatment of Mediterranean spotted fever in children: A randomized controlled trial / A. Cascio, C. Colomba, S. Antinori, D.L. Paterson, L. Titone. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 34:2(2002), pp. 154-158. (Intervento presentato al 11. convegno European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) tenutosi a Istanbul nel 2001) [10.1086/338068].
Abstract:
We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (± standard deviation) was 46.2 ± 36.4 h in the clarithromycin group and 39.3 ± 31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromycin and azithromycin could be acceptable therapeutic alternatives to chloramphenicol and tetracyclines for children aged ≥8 years with Mediterranean spotted fever. Azithromycin, because it has a long half-life, offers the advantages of administration in a single daily dose and a shorter duration of therapy, which could increase compliance in children.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
In-vitro suceptibilities; immunofluorescent-antibody analysis; vero-cell monolayers; rickettsia-rickettsII; boutonneuse-fever; climatic factors; conorII; epidemiology; erythromycin; doxycycline
Elenco autori:
A. Cascio, C. Colomba, S. Antinori, D.L. Paterson, L. Titone
Link alla scheda completa:
Link al Full Text: